- Report
- February 2024
- 70 Pages
Iran
From €4231EUR$4,750USD£3,682GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4231EUR$4,750USD£3,682GBP
- Report
- February 2024
- 70 Pages
Russia
From €4231EUR$4,750USD£3,682GBP
- Report
- February 2024
- 70 Pages
Australia
From €4231EUR$4,750USD£3,682GBP
- Report
- February 2024
- 70 Pages
China
From €4231EUR$4,750USD£3,682GBP
- Report
- February 2024
- 70 Pages
Japan
From €4231EUR$4,750USD£3,682GBP
- Report
- February 2024
- 70 Pages
Japan
From €4231EUR$4,750USD£3,682GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4231EUR$4,750USD£3,682GBP
- Report
- August 2023
- 70 Pages
Spain
From €4231EUR$4,750USD£3,682GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4231EUR$4,750USD£3,682GBP
- Report
- October 2022
- 70 Pages
Africa
From €4231EUR$4,750USD£3,682GBP
- Report
- February 2024
- 181 Pages
Europe
From €4231EUR$4,750USD£3,682GBP
- Report
- February 2024
- 150 Pages
Global
From €4231EUR$4,750USD£3,682GBP
- Report
- February 2024
- 143 Pages
Global
From €4231EUR$4,750USD£3,682GBP
- Report
- February 2024
- 85 Pages
North America
From €4231EUR$4,750USD£3,682GBP
- Report
- August 2023
- 150 Pages
North America
From €4231EUR$4,750USD£3,682GBP
- Report
- May 2023
- 160 Pages
Global
From €4409EUR$4,949USD£3,836GBP

Novorapid is a brand of insulin analogs used to treat endocrine and metabolic disorders. It is a fast-acting insulin that is used to control blood sugar levels in people with diabetes. Novorapid is a recombinant human insulin analog that is produced by recombinant DNA technology. It is designed to act faster and more predictably than regular human insulin. It is used to treat both type 1 and type 2 diabetes. Novorapid is administered subcutaneously and is usually taken before meals. It is used to control postprandial glucose levels and to prevent long-term complications of diabetes.
The Novorapid market is highly competitive, with several companies offering insulin analogs. These include Novo Nordisk, Eli Lilly, Sanofi, Merck, and Boehringer Ingelheim. Each company offers a range of insulin analogs, including Novorapid, to meet the needs of people with diabetes. Show Less Read more